Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Inclusion Criteria

• Diagnosis of the following tumor types
• Non Hodgkin-lymphoma, including:
• Diffuse large B-cell lymphoma: Histopathologic confirmation
• Mantle cell lymphoma: Histopathologic confirmation
• Follicular lymphoma, all grades: Histopathologic confirmation
• Marginal zone lymphoma: Histopathologic confirmation
• Chronic lymphocytic leukemia: Histopathologic or flow cytometric confirmation
• Multiple myeloma: Histopathologic or flow confirmation
• Relapsed, refractory, or detectable disease after treatment with chimeric antigen receptor T-cells
• Multiple Myeloma: patients must have exhausted all treatment options known to provide clinical benefit, and are refractory to a minimum of 3 prior lines of therapy (including an immunomodulatory imide drug [IMiD], proteasome inhibitor [PI], or anti-CD38 monoclonal antibody)
• Have measurable disease, defined by histology:
• Non-Hodgkin's lymphoma, based on presence of lesions >= 1.5 cm that can be accurately measured in 2 dimensions by computed tomography (CT) (preferred) or magnetic resonance imaging (MRI), and are not included in any prior field of radiation therapy
• Chronic lymphocytic leukemia: circulating lymphocytes >= 5,000 / mm^3
• Multiple myeloma, based on the International Myeloma Working Group (IMWG) criteria of having one or more of the following findings:
• Serum M protein >= 1.0 g/dL
• Urine M protein >= 200 mg/24 hours
• Involved serum free light chain level >= 10 mg/dL with abnormal kappa/lambda ratio
• Measurable biopsy-proven plasmacytomas (>= 1 lesion has a single diameter >= 2 cm)
• Bone marrow plasma cells >= 30%
• Age 18 years and older, and have the capacity to give informed consent
• Anticipated survival of > 3 months
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Post CAR T cell receipt of intervening palliative radiation therapy is allowed
• Estimated glomerular filtration rate (eGFR) >= 20 ml/min
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = = 1,000/uL
• Platelets >= 50,000/uL
• Hemoglobin >= 8 g/dL

Exclusion Criteria

• Receipt of intervening therapy after CAR T-cell infusion
• History of another primary malignancy that has not been in remission for at least 1 year (with the exception of non-melanoma skin cancer, curatively treated localized prostate cancer, curatively treated superficial bladder cancer and cervical carcinoma in site on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
• Active hepatitis B, hepatitis C at time of screening
• Known (human immunodeficiency virus [HIV]) seropositivity
• Subjects with uncontrolled infection
• Concurrent use of other anticancer agents or experimental treatments
• Active autoimmune disease requiring immunosuppressive therapy with the exception of vitiligo and autoimmune alopecia
• Known active central nervous system (CNS) involvement
• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses are permitted in absence of active autoimmune disease
• Known history of any active infectious pneumonitis
• Presence of acute or chronic graft-versus-host disease (GVHD) requiring active treatment unless limited to skin involvement and managed with topical steroid therapy alone
• Has active cytokine release syndrome
• Pregnancy or breastfeeding: Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (urine pregnancy test: minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 14 days of the first dose of study drug. Women must not be breastfeeding. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Females of childbearing potential and males who have